"10.1371_journal.pone.0013839","plos one","2010-11-04T00:00:00Z","Alvar Gr√∂nberg; Louise Zettergren; Kerstin Bergh; Mona St√•hle; Johan Heilborn; Kristian √Ñngeby; Pamela L Small; Hannah Akuffo; Sven Britton","Molecular Dermatology, Department of Medicine, Center for Molecular Medicine, Karolinska Institute, Stockholm, Sweden; Department of Dermatology and Venereology, Karolinska University Hospital, Stockholm, Sweden; Department of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden; Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden; Department of Microbiology, University of Tennessee, Knoxville, Tennessee, United States of America; Unit of Infectious Medicine, Karolinska University Hospital, Stockholm, Sweden","Conceived and designed the experiments: AG MS JH K√ HA SB. Performed the experiments: AG LZ KB. Analyzed the data: AG LZ KB. Contributed reagents/materials/analysis tools: K√ PLCS. Wrote the paper: AG. Initiated the project: SB.","A.G. is and L.Z. was employed by Lipopeptide AB (Stockholm, Sweden). M.S. and J.H. are founders and shareholders of Lipopeptide AB. This does not alter the authors adherence to all the PLoS ONE policies on sharing data and materials. Lipopeptide AB is developing a wound healing product intended for hard-to-heal venous leg ulcers (www.lipopeptide.se). The company has no products on the market. Lipopeptide gave limited support to this work but has denied rights regarding the work presented in this manuscript to A.G. No patent has been filed on work involving research on Buruli ulcers by the company or its employees.","2010","11","Alvar Gr√∂nberg","AG√",9,TRUE,6,3,3,1,TRUE,TRUE,FALSE,0,NA,FALSE
